Article: First Scientific Data for Lybrel(TM) Presented at ASRM Meeting.

- Presentation of Landmark Data on Investigational Low-Dose Oral Contraceptive Designed to Stop Hormonal Fluctuations Associated With the Entire Menstrual Cycle -

MADISON, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced that four scientific abstracts regarding Lybrel(TM) (0.09 mg levonorgestrel/0.02 mg ethinyl estradiol tablets) were presented for the first time today at the 61st Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Montreal, Canada. The studies investigated the effects of 0.09 mg levonorgestrel/0.02 mg ethinyl estradiol on ovarian activity, safety and efficacy, endometrial ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!